Literature DB >> 30840285

Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma.

X-B Xiao1, Y Gu, D-L Sun, L-Y Ding, X-G Yuan, H-W Jiang, Z-X Wu.   

Abstract

OBJECTIVE: The aim of this study was to investigate the influence of rituximab combined with chemotherapy on the expression of serum exosome micro ribonucleic acid 451a (miR-451a) in patients with diffuse large B-cell lymphoma (DLBCL), and to explore the possible underlying mechanism. PATIENTS AND METHODS: 89 DLBCL patients (DLBCL group) receiving rituximab combined with chemotherapy were enrolled in this study. Meanwhile, 48 healthy controls (control group) were enrolled as well. Serum samples were collected from all patients before and after treatment, respectively. At the same time, blood samples of healthy people were collected, and serum exosome was extracted. Real-Time fluorescence-quantitative Polymerase Chain Reaction (qRT-PCR) was applied to measure the expression level of serum exosome miR-451a. Receiver operating characteristics (ROC) curve was used to evaluate the diagnostic efficiency of miR-451a. Statistical Product and Service Solutions (SPSS) 22.0 was employed for statistical analysis. Two-sided 95% confidence interval (CI) was used for all tests, and p<0.05 was considered statistically significant.
RESULTS: The expression level of miR-451a in the DLBCL group was significantly lower than that of the control group. The area under the ROC curve (AUC) for the diagnostic efficacy of serum exosome miR-451a for DCBCL was 0.7147. After treatment, the level of serum exosome miR-451a in patients was significantly increased, whereas was still lower than the normal level. The AUC of ROC for evaluating the effect of serum exosome miR-451a in DCBCL was 0.8038.
CONCLUSIONS: Serum exosome miR-451a has moderate diagnostic efficiency for DLBCL. Moreover, miR-451a can act as an indicator for evaluating the efficacy of rituximab combined with chemotherapy in the DLBCL treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30840285     DOI: 10.26355/eurrev_201902_17121

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms.

Authors:  Somayeh Yazdanparast; Zoufang Huang; Shayan Keramat; Mehrdad Izadirad; Yi-Dong Li; Letao Bo; Ahmad Gharehbaghian; Zhe-Sheng Chen
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 2.  Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.

Authors:  Philippe Decruyenaere; Fritz Offner; Jo Vandesompele
Journal:  Exp Hematol Oncol       Date:  2021-02-16

Review 3.  Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma.

Authors:  Liwei Lv; Yuanbo Liu
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

Review 4.  The emerging role non-coding RNAs in B cell-related disorders.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Cancer Cell Int       Date:  2022-02-22       Impact factor: 5.722

5.  Investigation of canine extracellular vesicles in diffuse large B-cell lymphomas.

Authors:  Marek Kulka; Kieran Brennan; Margaret Mc Gee
Journal:  PLoS One       Date:  2022-09-20       Impact factor: 3.752

6.  Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.

Authors:  Di Cao; Xia Cao; Yu Jiang; Juan Xu; Yuhuan Zheng; Deying Kang; Caigang Xu
Journal:  Hematol Oncol       Date:  2021-12-17       Impact factor: 4.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.